New York University

New York University's Long Island School of Medicine operates as a federal grant recipient conducting biomedical and clinical research across cardiovascular disease, diabetes, and public health programs, with 57% of recent federal awards received as a prime grantee and 43% as a sub-recipient under larger federal research initiatives. The institution is not a federal contractor and does not hold prime contract vehicles; it participates exclusively in the grant ecosystem.

The school's research portfolio concentrates on NIH-funded biomedical science with applied clinical endpoints. Representative prime grant work includes a $2.73 million National Heart, Lung, and Blood Institute (NHLBI) Project Grant awarded September 24, 2025 (CFDA 93.837, Cardiovascular Diseases Research program) to develop and validate C2, a synthetic microRNA-30c analog targeting plasma cholesterol reduction and atherosclerosis mitigation; a $201,744 NHLBI Career Development (K23) grant awarded June 5, 2026 (CFDA 93.837) supporting Dr. Arabadjian's transition to independent investigator status focused on cardiovascular health promotion among socially vulnerable mothers using implementation science and community health worker-led interventions; and a $700,000 Centers for Disease Control and Prevention (CDC) cooperative agreement awarded September 30, 2025 (CFDA 93.988, Diabetes Prevention and Control Programs) positioning NYU Langone Health's Coordinating Center for CASSIDY (NYU COC) as a technical assistance and program management hub for diabetes prevention initiatives, including National Diabetes Prevention Program implementation and social determinants work across priority populations through September 2029. Additional prime-funded work spans translational lipid metabolism research, circadian regulation of macrophage cholesterol handling, and prostate cancer management disparity studies funded through NHLBI and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) extending through 2028.

Customer concentration is heavily skewed toward NIH components within Health and Human Services. The top five funding agencies account for 74% of recent awards: NHLBI leads with eight awards; NIDDK follows with seven; the National Institute of Neurological Disorders and Stroke holds five; CDC holds three; and the National Institute for Minority Health and Health Disparities holds three. The school serves twelve distinct federal agencies across its award footprint. In its sub-recipient role, NYU Long Island serves as a research site and technical contributor on multi-institutional initiatives including atrial fibrillation monitoring trials (Northwestern University prime), pain resolution mechanism studies (Cincinnati University prime), inflammatory bowel disease outcomes research (University of North Carolina prime), cervical cancer stigma reduction intervention work (University of Pennsylvania prime), and agent-based epidemiological modeling (University of Hawaii prime).

Activity has grown from four awards in 2022 to a peak of eight in 2024, with a decline to five awards in 2025 and one award recorded in 2026 year-to-date. Seven awards carry ultimate completion dates within the next twenty-four months, representing recompete or renewal opportunity for the institution. Combined obligated funding across all 35 awards totals $90 million. The school's federal footprint reflects a research institution model: no contract prime seat, full concentration on peer-reviewed NIH grant mechanisms (R01s, K23 career development, cooperative agreements, and multi-project program grants), heavy emphasis on cardiovascular and metabolic disease translation, and positioning as either lead investigator or specialized collaborator on multi-site clinical and implementation science networks.